Yukai Jia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yukai Jia has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Changyong Yu
College of Computer Science and Engineering, Northeastern University, Shenyang, Liaoning, China
1 shared publication - Haitao Ma
College of Computer Science and Engineering, Northeastern University, Shenyang, Liaoning, China
1 shared publication - Yuhai Zhao
Northeastern University, Shenyang, China
1 shared publication - Ze Li
Northeastern University
1 shared publication - Zhihao Wang
College of Computer Science and Engineering, Northeastern University, Shenyang, Liaoning, China
1 shared publication
Latest Publications
- 1 May 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Computational Biology and Bioinformatics
- Vol. 23 (3) , 1463-1474
Prediction of Cancer Drug Response Based on Hypergraph Convolutional Network and Contrastive Learning
Objective: Accurate prediction of cancer drug responses is essential for advancing precision oncology. This work aims to improve generalization and robustness in drug response prediction by modeling complex drug–cell line interactions. Methods: We propose HypergraphCDR, a Hypergraph Convolutional Network model with Hypergraph Contrastive Learning for cancer drug response prediction. Multiomics features of cancer cell lines are first compressed using an autoencoder. A Hypergraph is then constructed to capture high-order relationships between drugs and cancer cell lines, with Hypergraph Convolutional Networks generating drug embeddings. In parallel, cell line embeddings are generated via a neural network. Drug and cell line embeddings are jointly optimized and integrated into a regression framework using a combination of supervised regression loss and contrastive loss. Results: Extensive experiments demonstrate that HypergraphCDR consistently outperforms state-of-the-art methods in terms of Pearson Correlation Coefficient (${PCC}$), Spearman Correlation Coefficient (${SCC}$), and Coefficient of Determination (${R}^{2}$). Moreover, in independent experiments involving unseen drugs and unseen cell lines, as well as tissue-specific evaluations, HypergraphCDR exhibits superior generalization performance compared with recent baselines. Conclusion: By explicitly modeling higher-order drug–cell line relationships, HypergraphCDR substantially enhances the accuracy and robustness of cancer drug response prediction. Significance: This study provides an effective and generalizable computational framework for drug response prediction, supporting reliable drug screening and treatment strategy development in precision medicine.
- 1 May 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Transactions on Computational Biology and Bioinformatics
- Vol. 23 (3) , 1463-1474
Prediction of Cancer Drug Response Based on Hypergraph Convolutional Network and Contrastive Learning
Objective: Accurate prediction of cancer drug responses is essential for advancing precision oncology. This work aims to improve generalization and robustness in drug response prediction by modeling complex drug–cell line interactions. Methods: We propose HypergraphCDR, a Hypergraph Convolutional Network model with Hypergraph Contrastive Learning for cancer drug response prediction. Multiomics features of cancer cell lines are first compressed using an autoencoder. A Hypergraph is then constructed to capture high-order relationships between drugs and cancer cell lines, with Hypergraph Convolutional Networks generating drug embeddings. In parallel, cell line embeddings are generated via a neural network. Drug and cell line embeddings are jointly optimized and integrated into a regression framework using a combination of supervised regression loss and contrastive loss. Results: Extensive experiments demonstrate that HypergraphCDR consistently outperforms state-of-the-art methods in terms of Pearson Correlation Coefficient (${PCC}$), Spearman Correlation Coefficient (${SCC}$), and Coefficient of Determination (${R}^{2}$). Moreover, in independent experiments involving unseen drugs and unseen cell lines, as well as tissue-specific evaluations, HypergraphCDR exhibits superior generalization performance compared with recent baselines. Conclusion: By explicitly modeling higher-order drug–cell line relationships, HypergraphCDR substantially enhances the accuracy and robustness of cancer drug response prediction. Significance: This study provides an effective and generalizable computational framework for drug response prediction, supporting reliable drug screening and treatment strategy development in precision medicine.